Myriad Genetics, Inc. (MYGN)
NASDAQ: MYGN · Real-Time Price · USD
4.250
+0.360 (9.25%)
At close: May 12, 2025, 4:00 PM
4.250
0.00 (0.00%)
After-hours: May 12, 2025, 7:58 PM EDT
Myriad Genetics Stock Forecast
Stock Price Forecast
The 15 analysts with 12-month price forecasts for Myriad Genetics stock have an average target of 16.63, with a low estimate of 6.00 and a high estimate of 30. The average target predicts an increase of 291.29% from the current stock price of 4.25.
Analyst Consensus: Hold
Analyst Ratings
The average analyst rating for Myriad Genetics stock from 16 stock analysts is "Hold". This means that analysts believe this stock is likely to perform similarly to the overall market.
Recommendation Trends
Rating | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 | May '25 |
---|---|---|---|---|---|---|
Strong Buy | 2 | 1 | 2 | 2 | 2 | 2 |
Buy | 2 | 2 | 3 | 4 | 4 | 3 |
Hold | 6 | 6 | 6 | 6 | 7 | 8 |
Sell | 3 | 3 | 3 | 3 | 3 | 3 |
Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Total | 13 | 12 | 14 | 15 | 16 | 16 |
Latest Forecasts
Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
---|---|---|---|---|---|---|---|
Wells Fargo | Wells Fargo | Buy → Hold Downgrades $22 → $6 | Buy → Hold | Downgrades | $22 → $6 | +41.18% | May 8, 2025 |
Goldman Sachs | Goldman Sachs | Strong Buy Maintains $14 → $8 | Strong Buy | Maintains | $14 → $8 | +88.24% | May 7, 2025 |
UBS | UBS | Hold Maintains $16 → $7 | Hold | Maintains | $16 → $7 | +64.71% | May 7, 2025 |
Raymond James | Raymond James | Buy Reiterates $19 → $10 | Buy | Reiterates | $19 → $10 | +135.29% | May 7, 2025 |
Goldman Sachs | Goldman Sachs | Strong Buy Maintains $18 → $14 | Strong Buy | Maintains | $18 → $14 | +229.41% | Apr 17, 2025 |
Financial Forecast
Revenue This Year
862.43M
from 837.60M
Increased by 2.96%
Revenue Next Year
934.57M
from 862.43M
Increased by 8.36%
EPS This Year
0.08
from -1.41
EPS Next Year
0.28
from 0.08
Increased by 250.15%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|
High | 899.0M | 984.8M | 1.1B | ||
Avg | 862.4M | 934.6M | 1.0B | ||
Low | 803.8M | 833.3M | 865.1M |
Revenue Growth
Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|
High | 7.3% | 14.2% | 16.5% | ||
Avg | 3.0% | 8.4% | 7.5% | ||
Low | -4.0% | -3.4% | -7.4% |
EPS Forecast
EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|
High | 0.11 | 0.43 | 0.74 | ||
Avg | 0.08 | 0.28 | 0.47 | ||
Low | 0.01 | 0.09 | 0.26 |
EPS Growth
EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|
High | - | 445.8% | 166.1% | ||
Avg | - | 250.1% | 70.9% | ||
Low | - | 11.8% | -4.2% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.